生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

2'-FL：母乳关键成分，赋能健康营养 作为母乳中含量最高（约30%）的人乳寡糖，2'-FL具有显著的营养与医学价值：促进婴幼儿生长发育及认知能力；增强 免疫力，抗病毒、抗过敏；调节肠道菌群平衡。其应用已覆盖多国婴幼儿配方奶粉，是极具潜力的新型营养强化剂。 未来食品&农业 | 柯泰亚 关于柯泰亚 【SynBioCon】 获 悉 ， 柯泰亚生物科技（上海）有限公司（以下简称"柯泰亚"）宣布，其自主研发的母乳低聚糖 （HMO）核心产品 2'-岩藻糖基乳糖 (2'-FL) 正式通过美国食品药品监督管理局 (FDA) 的GRAS (一般认为安全， Generally Recognized As Safe) 认证。 2025年初柯泰亚向FDA提交了关于2'-FL作为食品配料的申请，2025年6月18日收到FDA的"No Question Letter"， 确认柯泰亚2'-FL可作为食品添加剂应用于婴儿配方奶粉、儿童食品及传统食品及饮料 。此举标志着柯泰亚成为国内少数 获得该认证的本土企业，其研发创新、生产质量与安全管控体系获得国际权威认可。 此次认证是柯泰亚凭借自主知识产权进军全球HMO市场的重要突破。获得FDA GR ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the 14th Five-Year Plan, exploring new products, technologies, and collaborations [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry players, top universities, and capital from various sectors will gather to discuss advancements in biomanufacturing [4]. Group 4: Special Activities and Agenda - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [7]. - The second and third days will feature a macro forum on biomanufacturing, covering the development trends and progress of policies related to the industry [10]. Group 5: Specialized Forums - The conference will host specialized forums on various topics, including green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - Each forum will address specific themes such as the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11].

Core Viewpoint - The article discusses the advancements in synthetic biology tools for customizing yeast cell factories, highlighting their potential in producing high-value compounds efficiently [3]. Group 1: Innovative Tools for Yeast Cell Factories - The paper titled "Innovative tools for customized yeast cell factory" outlines significant progress in synthetic biology tools, including genome editing, computational tools, adaptive laboratory evolution, and standardization of biological DNA components [3]. - These tools aim to provide practical guidelines for the effective development of customized yeast cell factories [3]. Group 2: Genome Editing Tools - Genome editing has evolved from single-gene editing to simultaneous multi-gene editing, with CRISPR-Cas systems enabling precise modifications in yeast genomes, including knockouts, insertions, and replacements [6]. - New variants of CRISPR-Cas, such as base editing and prime editing, allow for single nucleotide changes to alter gene functions [6]. Group 3: Computational Tools - Computational tools, including metabolic modeling and the integration of omics technologies, guide engineering strategies and expected flux adjustments [7]. - Genome-scale metabolic models (GEMs) have been widely applied in yeast metabolic engineering, with large-scale kinetic models playing a crucial role in designing and understanding metabolic reactions [7]. Group 4: Adaptive Laboratory Evolution - Adaptive laboratory evolution (ALE) is a powerful strategy for enhancing yeast strain performance by applying selective pressure over generations, leading to the emergence of more adaptive strains [8]. - Combining ALE with whole-genome sequencing helps identify beneficial mutations and provides insights into the genetic basis of adaptability [8]. Group 5: Standardization of Biological DNA Components - The increasing complexity of yeast cell factory designs necessitates precise control and regulation of biological components, gene circuits, or biological systems [9]. - Synthetic biology offers standardized biological components, allowing researchers to assemble these components into complex systems with predictable behaviors [9].

Core Viewpoint - Xinhua Medical, a leading enterprise in China's medical device industry, will participate in the SynBioCon 2025, focusing on synthetic biology and green bio-manufacturing [1][29]. Company Overview - Shandong Xinhua Medical Instrument Co., Ltd. was established in 1943 and is a comprehensive leader in the medical device industry in China, specializing in nine core areas including laboratory technology, infection control, radiological diagnosis, and surgical instruments [10]. - As the top company in the domestic infection control equipment market, Xinhua Medical has a national-level enterprise technology center and has participated in the formulation of over a hundred industry standards, with products exported to more than 100 countries and regions [11]. Technological Focus - In the laboratory technology sector, Xinhua Medical focuses on cytology and microbiology, aiming for breakthroughs in laboratory automation and providing various standalone and systematic solutions to support high-quality development in laboratory research [12]. - The company employs advanced technologies such as fully automated cell culture, AI algorithm recognition, multi-axis collaborative robotic arms, and efficient hydrogen peroxide sterilization to address issues like inconsistent cell culture and low survival rates during subculturing [13]. Product Offerings - Xinhua Medical offers a range of products including: - Fully automated microbiological sample processing systems for food safety, biomedicine, environmental monitoring, and public health [15]. - CO2 incubators designed for biopharmaceutical companies and research institutions, featuring patented airflow and smart IoT technology for optimal cell culture environments [16]. - Vertical sterilizers for various research institutions and medical facilities, equipped with features like automatic drainage and biological safety design [17]. - Hydrogen peroxide disinfectors capable of sterilizing air in closed spaces, achieving a log6 sterilization level [19]. - Cell counters that utilize intelligent image recognition for precise cell analysis in various research fields [21]. - Automated culture medium dispensing systems for hospitals and laboratories, enhancing efficiency and reducing manual labor [23]. Industry Event - The SynBioCon 2025 will take place from August 20-22 in Ningbo, Zhejiang, focusing on AI and biological manufacturing, as well as four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [29].

点击更多阅读 ： 工信部又发文，事关非粮生物基材料产业！ 在当今发酵行业，碳源成本问题一直困扰着众多企业。传统碳源多依赖于粮食作物，不仅价格高昂、波动频繁，还面临着与民争粮的矛盾。与此同时， 我国政策逐渐重视非粮生物基产业布局。 突破非粮碳源的生物制造技术与相关企业受到行业高度关注。 其中， 青岛碧沃德生物科技有限公司 凭借多年 生物柴油行业 积累的技术与资源，突破常规，研发出 滤膜碳源 和 合生甘霖碳源 两种新型非粮碳源， 为发酵行业带来全新变革。 传统发酵碳源主要来源于糖类，如葡萄糖等，价格居高不下且波动大。 以 PHA 生产为例，仅碳源成本就占生产过程的 40%-50% ，每千克生产成本高达 2-8 美元 。这不仅增加了企业的生产成本，也给粮食安全带来了潜在风险。 青岛碧沃德生物科技有限公司另辟蹊径，从油脂行业副产物中寻找解决方案。公司改进传统生产工艺，开发出滤膜碳源和合生甘霖碳源两种新型非粮碳 源。 这两种碳源以乙酸钠和丙三醇为主要成分，含有多种促进微生物生长的小分子有机酸、维生素等营养成分，适用多种微生物培养 。它们不仅降低了对 粮食作物的依赖，还降低了碳源成本，稳定供应市场，符合 RED Ⅲ欧盟先 ...

Core Viewpoint - The K&K team from Nanjing University of Technology has successfully industrialized over 500,000 tons per year of high-performance bio-based materials, showcasing the potential of bio-based materials in various applications and their advantages over petroleum-based materials [1][2]. Group 1: Advantages of Bio-based Materials - Bio-based materials allow for precise structural tuning, overcoming the limitations of traditional petrochemical materials which have a single structure and are difficult to modify [4][5]. - The natural endowment of raw materials, such as amino acids and lignin, provides significant advantages over petrochemical raw materials, enabling more efficient polymerization processes [6]. - Bio-based materials contribute to a closed-loop resource cycle, enhancing sustainability [6]. Group 2: K&K Team's Successful Strategies - The K&K team emphasizes integrated research rather than isolated studies, focusing on fundamental research to explore micro-scale effects and overcome engineering bottlenecks, resulting in over 300 published SCI papers [7][8]. - They have developed common technologies and engineering equipment, securing over 20 international patents and completing the application transformation of more than 60 patents [8][9]. - The team has achieved significant cost reductions of over 65% in production through technological innovations in multi-component processes and polymerization [9]. Group 3: Product Applications and Achievements - The K&K team has established a comprehensive product system based on common biomass raw materials, achieving over 500,000 tons per year of bio-based materials [10][11]. - Notable products include bio-based polyurethane (50,000 + 150,000 tons/year), bio-based plasticizers, and bio-based spandex, with several products receiving global bio-based material certifications [13][17]. - These materials have been applied in major engineering projects, including the Belt and Road Initiative and various infrastructure developments [14][16].

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （现场展示科技成果推介墙）， 公开征集100个从0—1—100的合成生物和生物制造领域创新成果 和项目 ，于现场展示、对接。 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30 ...

全球政策进展 | 上海市 2025 年度关键技术研发计划 "合成生物学 "项目立项清单 | 序号 | 1 | | --- | --- | | 项目编号 | 25HC2810100 | | | 基于喷墨打印微阵列芯片的高通量高精度 | | 项目名称 | 低成本长片段核酸合成 | | 项目承担单位 | 上海迪赢生物科技有限公司 | | 项目负责人 | 张满仓 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 2 | | 项目编号 | 25HC2810200 | | 项目名称 | 高通量长片段 DNA 酶促合成系统研发 | | 项目承担单位 | 上海人工智能研究院有限公司 | | 项目负责人 | 夏 凯 | | 项目实施周期 | 2025.08.01-2028.07.31 | | 序号 | 3 | 项目编号 25HC2810300 项目名称 重要天然产物生物合成功能元件挖掘及共 享元件库的构建 项目承担单位 上海中医药大学 项目负责人 陈万生 项目实施周期 2025.08.01-2028.07.31 序号 4 项目编号 25HC2810400 项目名称 生物合成新元件的挖掘表征 ...

Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. **Long-chain dicarboxylic acid production line**: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. **Bio-fermentation functional products production line**: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. **Bio-food production line**: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. **Amino acid products production line**: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].